Sight Sciences, Inc. (NASDAQ: SGHT) is a Healthcare company (Medical - Devices) with a market capitalization of $607M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Sight Sciences, Inc. had a Maz Rating of 3.64 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (3.62), above most of its sector; its weakest was Valuation (2.54), valued in line with its sector. The other factors: Profitability 3.45 (around the middle of its sector); Growth 3.18 (around the middle of its sector); Financial Health 3.14 (around the middle of its sector). The current rating is for members: log in to see it.
At $10.92, Sight Sciences, Inc. trades at 6.8x sales and 12.1x book value. Over the last twelve months it generated about $90M of revenue and a net loss of $29M. It runs a gross margin of 87.7%, an operating margin of -29.5% and a net margin of -32.1%. It shows return on equity of -51.7%, return on invested capital of -28.6% and a free cash flow yield of -2.8%. On the balance sheet: a debt-to-equity ratio of 0.86 and a current ratio of 5.04. Over the past 52 weeks the share price ranged from $3.38 to $11.16, with a beta of 2.43.
Sight Sciences, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 4 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.